Modulation of the human gut microflora towards improve health using prebiotics - Assessment of efficacy

Current Pharmaceutical Design

Volumn 11, Issue 1, 2005, Pages 75-90

  Tuohy, K M ^a   Rouzaud, G C M ^a   Bruck W M ^a   Gibson, G R ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Bifidobacteria; Functional food; Gut microflora; Oligosaccharides; Prebiotic

Indexed keywords

AZO REDUCTASE; BETA GLUCURONIDASE; BUTYRIC ACID; CELLULOSE; FRUCTOSE OLIGOSACCHARIDE; GALACTOOLIGOSACCHARIDE DERIVATIVE; GALACTOSE; GENTIOOLIGOSACCHARIDE DERIVATIVE; GLUCOOLIGOSACCHARIDE DERIVATIVE; GLUTAMINE; GUAR GUM; INULIN; ISOMALTO 900; ISOMALTOOLIGOSACCHARIDE DERIVATIVE; LACTITOL; LACTOSUCROSE; LACTULOSE; NITROREDUCTASE; OLIGOSACCHARIDE; PENTICOLIGOSACCHARIDE DERIVATIVE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; SIALIC ACID; SORBITOL; SOYOLIGOSACCHARIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; XYLOOLIGOSACCHARIDE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL MILK; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; BREAST FEEDING; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DOSE REGIMEN; DRUG EFFICACY; ENTERITIS; ENZYME INHIBITION; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL INFECTION; HEALTH STATUS; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; LACTOBACILLUS; METABOLITE; NECROTIZING ENTEROCOLITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; GASTROINTESTINAL TRACT; HEALTH STATUS; HUMANS; PROBIOTICS;

EID: 12144273621     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382331     Document Type: Review

References (173)

1. Moore WEC, Holdeman LV. Human faecal biota: the normal biota of 20 Japanese-Hawaiians. Appl Microbiol 1974; 27: 961-79.
2. Conway PL. Microbial ecology of the human large intestine. In: Gibson GR, Macfarlane GT Eds. Human colonic bacteria: role in nutrition, physiology and pathology. Boca Raton, CRC Press 1995; 1-24.
3. Macfarlane GT, Gibson GR. Carbohydrate fermentation, energy transduction and gas metabolism in the human large intestine. In: Mackie RI, White BH Eds. Gastrointestinal Microbiology. London, Chapman & Hall 1997; 269-318.
4. Veilleux BG, Rowland IR. Simulation of the rat intestinal ecosystem using a two-stage continuous culture system. J Gen Microbiol 1981; 123: 103
5. Hentges DJ. Gut flora and disease resistance. In: Fuller R Ed, Probiotics: The scientific basis. London, Chapman & Hall 1992; 87-110.
6. Raibaud P. Bacterial interactions in the gut. In Fuller R Ed, Probiotics: The scientific basis. London, Chapman & Hall 1992; 9-24.
7. Cummings JH, Pomare EW, Branch WJ, Naylor CPE, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-7.
8. Roediger WEW. The utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1989; 83: 424-9.
9. Williams EA, Coxhead JM, Mathers JC. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc Nutr Soc 2003; 62: 107-115.
10. Rafter J, Govers M, Martel P, Pannemans D, Pool-Zobel B, Rechkemmer G, et al. PASSCLAIM - diet -related cancer. Eur J Nutr 2004; 43: 1147-1184.
11. McCracken VJ, Gaskins HR. Probiotics and the immune system. In: Tannock GW ed. Probiotics a critical review. Wymondham, Horizon Scientific Press 1999; 85-111.
12. McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cellular Microbiology 2001; 3: 1-11.
13. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90-7.
14. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. Journal of Pediatrics 2001; 138: 361-5.
15. Tuohy KM, Probert HM, Smejkel CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Dis Today 2003; 8: 692-700.
16. Tannock GW. Probiotics and prebiotics: where are we going? In: Tannock GW Ed, Probiotics and prebiotics where are we going? Wymondham, Caister Academic Press 2002; 1-20.
17. Fuller R. History and development of probiotics. In: Fuller R Ed, Probiotics: the scientific basis. London, Chapman and Hall 1992; 1-7.
18. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-12.
19. Collins MD, Gibson GR. Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69: 1052S-57S.
20. Gibson GR, Berry-Ottaway P, Rastall RA. In: Prebiotics: new developments in functional foods. Oxford, Chandos Publishing Limited 2000.
21. Crittenden RG, Playne MJ. Production, properties and applications of food-grade oligosaccharides. Trends in Food Science and Technology 1996; 7: 353-61.
22. Crittenden RG. Prebiotics. In: Tannock G, Ed; Probiotics: a critical review. Wymondham, Horizan Scientific Press, 1999.
23. Roberfroid MB, Van Loo JAE, Gibson GR. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr 1998; 128: 11-9.
24. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 1994; 77: 412-20.
25. Wang X, Gibson GR. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J Appl Bacteriol 1993; 75: 373-80.
26. Sghir A, Chow JM, Mackie RI. Continuous culture selection of bifidobacteria and lactobacilli from human faecal samples using fructooligosaccharides as selective substrates. J Appl Microbiol 1998; 85: 769-77.
27. Kolida S, Tuohy K, Gibson GR. Prebiotic effects of inulin and oligofructose. Br J Nutr 2002; 87(Suppl 2): S193-S7.
28. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995; 108: 975-82.
29. Roberfroid MB. Health benefits of non-digestible oligosaccharides. Adv Exp Med Biol 1997; 427: 211-9.
30. Tuohy KM, Kolida S, Lustenberger AM, Gibson GR. The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides - a human volunteer study. Br J Nut 2001; 86: 341-8.
31. Saunders DR, Wiggins HS. Conservation of mannitol, lactulose and raffinose by the human colon. Am J Physiol 1981; 241: G397-G402.
32. Salminen S, Salminen E. Lactulose, lactic acid bacteria, intestinal microecology and mucosal protection. Scan J Gastroenterol 1997; 32 (Suppl 222): 45-8.
33. Terada A, Hara H, Kataoka M, Mitsuoka T. Effect of lactulose on the composition and metabolic activity of the human faecal microbiota. Microb Ecol Health Dis 1992; 5: 43-50.
34. Ballongue J, Grill JP, Baratteeuloge P. Effects of Bifidobacterium fermented milks on human intestinal flora. Lait 1993; 73 (2): 249-56.
35. Ballongue J, Schumann C, Quignon P. Effects of lactulose and lactitol on colonic microbiota and enzymatic activity. Scand J Gastroenterol 1997; 32: 41-4.
36. Tuohy KM, Ziemer CJ, Klinder A, Knöbel Y, Pool-Zobel BL, Gibson GR. A human volunteer study to determine the prebiotic effects of lactulose powder on human colonic microbiota. Microb Ecol Health Dis 2002; 14: 165-73.
37. Kolida S, Tuohy K, Gibson GR. The human gut flora in nutrition and approaches for its dietary modulation. Br Nut Bull 2000; 25: 223-31.
38. Bouhnik Y, Flourie B, D'Agay-Abensour L, Pochart P, Gramet G, Durand M, et al. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nut 1997; 127: 444-8.
39. Tanaka R, Takayama H, Morotomi M, Kuroshima T, Ueyama S, Matsumoto K, et al. Effects of administration of TOS and Bifidobacterium breve 4006 on the human faecal flora. Bif Microflora 1983; 2: 17-24.
40. Rycroft CE, Jones MR, Gibson GR, Rastall RA. A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. J Appl Microbiol 2001; 91: 878-87.
41. Sharp R, Fishbain S, Macfarlane GT. Effect of short-chain carbohydrates on human intestinal bifidobacteria and Escherichia coli in vitro. J Med Microbiol 2001; 50: 152-60.
42. Holma R, Juvonen P, Asmawi MZ, Vapaatalo H, Korpela R. Galacto-oligosaccharides stimulate the growth of bifidobacteria but fail to attenuate inflammation in experimental colitis in rats. Scand J Gastroenterol 2002; 37: 1042-1047.
43. Rowland IR, Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faccal microflora. J App Bacteriol 1993; 74: 667-74.
44. Ito M, Deguchi Y, Miyamori A, Matsumoto K, Kikuchi H, Matsumoto K, et al. Effects of administration of galactooligosaccharides on the human ecal microflora, stool weight and abdominal sensation. Microb Ecol Health Dis 1990; 3: 285-92.
45. Ito M, Deguchi Y, Matsumoto K, Kimura M, Onodera N, Yajima T. Influence of galactooligosaccharides on the human fecal microflora. J Nutr Vitaminol 1993; 39: 635-640.
46. Alles MS, Hartemink R, Meyboom S, Harryvan JL, Van Laere KMJ, Nagengast FM, et al. Effect of transgalactooligosaccharides on the composition of the human intestinal microflora and on putative risk markers for colon cancer. Am J Clin Nut 1999; 69: 980-91.
47. Olano-Martin E, Gibson GR, Rastall RA. Comparison of the in vitro bifidogenic properties of pectins and pectic-oliggosaccharides. J Appl Microbiol 2002; 93: 505-11.
48. Rastall RA, Maitin V. Prebiotics and synbiotics: towards the next generation. Cur Opin Biotechnol 2002; 13: 490-6.
49. Crittenden R, Laitila A, Forssell P, Matto J, Saarela M, Mattila-Sandholm T, et al. Adhesion of bifidobacteria to granular starch and its implications in probiotic technologies. Appl Environ Microbiol 2001; 67(8): 3469-75.
50. Wang, X, Brown IL, Khaled D, Mahoney MC, Evans AJ, Conway PL. Manipulation of colonic bacteria and volatile fatty acid production by dietary high amylose maize (amylomaize) starch granules. Journal of Applied Microbiology 2002; 93: 390-7.
51. Rabiu BA, Jay AJ, Gibson GR, Rastall RA. Synthesis and fermentation properties of novel galactooligosaccharides by β-galactosidase from Bifidobacterium species. Appl Environ Microbiol 2001; 67: 2526-30.
52. Kohmoto T, Fukui F, Takaku H, Machida Y, Arai M, Mitsuoka T. Effect of isomalto-oligosaccharides on human fecal flora. Bif Microflora 1988; 7: 61-9.
53. Mountzouris KC, Gilmour SG, Grandison A, Rastall RA. Modelling of oligodextran production in an ultrafiltration stirred cell membrane reactor. Enz Microb Technol 1998; 24: 75-85.
54. Kohmoto T, Fukui F, Takaku H, Mitsuoka T. Dose-response test of isomaltooligosaccharides for increasing fecal bifidobacteria. Agricul Biol Chem 1991; 55: 2157-9.
55. Kaneko T, Kohmoto T, Kikuchi H, Shiota M, Iino H, Mitsuoka T. Effects of isomaltooligosaccharides with different degrees of polymerisation on human fecal bifidobacteria. Biosci Biotechnol Biochem 1994; 58: 2288-90.
56. Hayakawa K, Mizutani J, Wada K, Masai T, Yoshihara I, Mitsuoka T. Effects of soybean oligosaccharides on human faecal flora. Microb Ecol Health Dis 1990; 3: 293-303.
57. Oku T. Special phyliologisal functions of newly developed mono- and oligosaccharides. In: Goldberg I Ed. Functional foods: resigner foods, pharma foods, nutraceutical. London, Chapman and Hall 1994; 202-7.
58. Saito Y, Takano T, Rowland I. Effects of soybean oligosaccharides on the human gut microflora in vitro culture. Microb Ecol Health Dis 1992; 5: 105-10.
59. Benno Y, Endo K, Shiragami N, Sayama K, Mitsuoka T. Effects of raffinose intake on human faecal microflora. Bif Microllora 1987; 6: 59-63.
60. Wada K, Watanabe J, Mizutani J, Tomoda M, Suzuki H, Saitoh Y. Effects of soybean oligosaccharides in a beverage on human fecal flora and metabolites. J Agri Chem Soc Japan 1992; 66: 127-135.
61. Hopkins MJ, Cummings JH, Macfarlane GT, Inter-species differences in maximum specific growth rates and cell yields of bifidobacteria cultured on oligosaccharides and other simple carbohydrate sources. J Appl Microbiol 1998; 85: 381-6.
62. Okazaki M, Fujikawa S, Matsumoto N. Effects of xylooligosaccharide on growth of bifidobacteria. J Japan Soc Nut Food Sci 1990; 43: 395-401.
63. Jaskari J, Kontula P, Siitonen A, Jousimies-Somer H, Mattila-Sandholm T, Poutanen K. Oat β-glucan and xylan hydrolysates as selective substrates for Bifidobacterium and Lactobacillus strains. Appl Microbiol Biotechnol 1998; 49: 175-181.
64. Campbell JM, Fahey GC, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass and fecal short-chain fatty acids, pH and microflora in rats. J Nut 1997; 127: 130-6.
65. Valette P, Pelenc V, Djouzi Z, Andrieux C, Paul F, Monsan P, et al. Bioavailability of new syntherised glucooligosaccharides in the intestinal tract of gnotobiotic rats. J Sci Food Agric 1993; 62: 121-7.
66. Djouzi Z, Andrieux C, Pelenc V, Somarriba S, Popot F, Paul F, et al. Degradation and fermentation of α -gluco-oligosaccharides by bacterial strains from human colon: in vitro and in vivo studies in gnotobiotic rats. J Appl Bacteriol 1995; 79: 117-27.
67. Tamura Z. Nutriology of bifidobacteria. Bif Microflora 1983; 2: 3-16.
68. Fujita K, Ogata Y, Hara K. Effect of 4 G-β-Galactosylsucrose (lactosucrose) on intestinal flora. Seito Gigutsu Kenkyukai-shi. 1995; 43: 83-91.
69. Hara H, Li S, Sasaki M, Maruyama T, Terada A, Ogata Y, et al. Effective dose of lactosucrose on fecal flora and fecal metabolites of humans. Bif Microflora 1994; 13: 51-63.
70. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881-4.
71. Harmsen HJM, Wildeboer-Veloo ACM, Raangs GC, Wagendorp AA, Klijn NN, Bindels JG, et al. Analysis of intestinal flora development in breast-fed and fomula-fed infants using molecular identification and detection methods. J Pediat Gastro-enterol Nut 2000; 30: 62-7.
72. Goldman AS. Modulation of the gastrointestinal tract of infants by human milk. Interfaces and interactions. An evolutionary perspective. J Nutr 2000; 130: 426S-31S.
73. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Cur Iss Infest Microbiol 2001; 2: 43-53.
74. Bullen CL, Tearle PV. Bifidobacteria in the intestinal tract of infants: an in vitro study. J Med Microbiol 1976; 9(3): 335-44.
75. Bullen CL, Tearle PV, Stewart MG. The effect of 'humanised' milks and supplemented breast-feeding on the faccal flora of infants. J Med Microbiol 1977; 10: 403-13.
76. Sabharwas H, Sjoblad S, Lundblad A. Affinity chromatographic identification and quantification of blood group A-active oligosaccharides in human milk and faeces of breast-fed infants. J Pediatr Gastroenterol Nutr 1991; 12: 474-9.
77. Engfer MB, Stahl B, Finke B, Sawatzki G, Daniel H. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am J Clin Nutr 2000; 71(6): 1589-96.
78. Kunz C, Rudloff S. Biological functions of oligosaccharides in human milk. Acta Paediatr 1993; 82: 903-12.
79. Stephens S, Dolby JM, Montreuik J, Spik G. Differences in inhibition ofthe growth of commensal and enteropathogenic strains of Escherichia coli by lactoferrin and secretory immunoglobulin A isolated from human milk. Immunology 1980; 41 (3): 597-603.
80. Gothefors L, Olling S, Winberg J. Breast feeding and biological properties of faecal E. coli strains. Acta Paediatr Scand 1975; 64: 807-12.
81. Rivero-Urgell M, Santamaria-Orleans A. Oligosaccharides: application in infant food. Early Hum Dev 2001; 65(Suppl.): S43-S52.
82. Bullen CL, Tearle PV, Willis AT. Bifidobacteria in the intestinal tract of infants: an in vivo study. J Med Microbiol 1976; 9(3): 325-33.
83. Parrett AM, Edwards CA. In vitro fermentation of carbohydrates by breast-fed and formula fed infants. Arch Dis Child 1997; 76(3): 249-53.
84. Moro G, Minoli I, Mosca M, Fanaro S, Jelinek J, Stahl B, et al. Dosage-related bifidogenic effects of galacto- and fructooligosaccharides in formula-fed term infants. J Pediatr Gastroenterol Nutr 2002; 34: 291-5.
85. Venturi M, Hambly RJ, Glinghammar B, Rafter JJ, Rowland IR. Genotoxic activity in human faecal water and the role of bile acids: a study using the alkaline comet assay. Carcinogenesis 1997; 18: 2353-9.
86. Rowland IR, Gangolli SD. Role of gastrointestinal flora in the metabolic and toxicological activities of xenobiotics. In: Ballantyne B, Marrs TC, Syverson T Eds, General and Applied Toxicology, 2nd Edition London, Macmillan Publishers Ltd. 1999; 561-76.
87. Burns AJ, Rowland IR. Anti-carcinogenicity of probiotics and prebiotics. Curr Iss Intest Microbiol 2000; 1: 13-24.
88. Gallaher DD, Khil J. The effect of synbiotics on colon carcinogenesis in rats. J Nut 1999; 129: 1483S-7S.
89. Reddy BS. Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. J Nut 1999; 129: 1478S-82S.
90. Rowland IR, Rumney CJ, Courts JT, Lievense LC. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998; 19: 281-5.
91. Terada A, Hara H. Kataoka M, Mitsuoka T. Effect of lactulose on the composition and metabolic activity of the human faecal flora. Microb Ecol Health Dis 1992; 5: 43-50.
92. Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, Rumney C, et al. Lactobacillus and Bifidobacterium mediated antigenotoxicity in the colon of rats. Nut Cancer 1996; 26: 365-80.
93. Rowland IR, Bearne CA, Fisher R, Pool-Zobel BL. The effect of lactulose on DNA damage induced by DMH in tile colon of human flora associated rats. Nut Cancer- an international journal 1996; 26(1): 37-47.
94. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Letters 1987; 37: 147-51.
95. Preflow TP, O'Riordan MA, Somitch GA, Amini SB, Pretlow TG. Aberrant crypts correlate with tumour incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992; 13: 1509-12.
96. Magnuson B, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colonic tumour incidence in rats fed cholic acid. Cancer Research 1993; 53: 4499-504.
97. Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amino-3-methylimidazo [4,5,F] quinoline, a food mutagen. Cancer Research 1993; 53(17): 3914-8
98. Kulkarni N, Reddy BS. Inhibtory effect of Bifidobacterium longum cultures on the azoxymethane induced aberrant crypt foci formation and fecal bacterial β-glucosidase. Proc Soc Exp Biol Med 1994; 207 (3): 278-83.
99. Abdelali H, Cassand P, Soussotte V, Daubeze M, Bouley C, Narbonne J. F. Effect of dairy products on initiation of precursor lesions of colon cancer in rats. Nutr Cancer 1995; 24(2): 121-32.
100. Wijnands MVW, Schoterman HC, Bruijntjes JP, Hollanders VMH, Woutersen RA. Effect of dietary galacto-oligosaccharides on azoxymethane induced aberrant crypt foci and colorectal cancer in Fischer 344 rats. Carcinogenesis 2001; 22: 127-32.
101. Reddy BS, Humid R, Rao CV. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis 1997; 18: 1371-4.
102. Rao CV, Chou D, Simi B, Ku H, Reddy BS. Prevention of colonic aberrant crypt foci and modulation of large bowel microbial activity by dietary coffee fiber, inulin, and pectin. Carcinogenesis 1998; 19: 1815-1819.
103. Verghese M, Rao DR, Chawan CB, Shackelford L. Dietary inulin suppresses azoxymethane-induced preneoplastic aberrant crypt foci in mature Fischer 344 rats. J Nutt 2002; 132: 2804-8.
104. Bolognani F, Rumney CJ, Pool-Zobel BL, Rowland IR. Effect of lactobacilli, bifidobacteria and inulin on the formation of aberrant crypt foci in rats. Eur J Nut 2001; 40: 293-300.
105. Challa A, Rao DR, Chawan CB, Shackelford L. Bifidobacterium longum and lactulose suppress azoxymethane induced aberrant crypt foci in rats. Carcinogenesis 1997; 18: 517-21.
106. Verghese M, Rao DR, Chawan CB, Williams LL, Shackelford L. Dietary inulin suppresses azoxymethane-induced aberrant crypt foci and colon tumors at the promotion stage in young Fischer 344 rats. J Nutr 2002; 132: 2809-2813.
107. Pierre F, Perrin P, Champ M, Bornet F, Meflah K, Menanteau J. Short-chain fructooligosaccharides reduce the occurrence of colon tumours and develop gut associated lymphoid tisseu in Min mice. Cancer Research 1997; 57: 225-8.
108. Zhang XB, Ohta Y. Microorganisms in the gastro-intestinal tract of the rat prevent absorption of the mutagen-carcinogen 3-amino-1, 4-dimethyl-5H-pyrido (4,3-b) indole. Can J Microbiol 1993; 39(9): 841-5.
109. Bolognani F, Rumnay CJ, Rowland IR. Influence of carcinogen binding by lactic acid producing bacteria on tissue distribution and in vivo mutagenicity of dietary carcinogens. Food Chem Toxicol 1997; 35(6): 535-45.
110. Perdigon G, Valdez JC, Rachid M. Antitumour activity of yoghurt: study of possible immune mechanisms. J Dairy Res 1998; 65(1): 129-38.
111. Csordas A. Toxicology of butyrate and short-chain fatty acids. In: MJ Ed. Role of gut bacteria in human toxicology and pharmacology. London, Taylor and Francis 1995; 105-25.
112. Tran CP, Familari M, Parker LM, Whitehead RH, Giraud AS. Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. Am J Physiol- Gastrointest Liver Physiol 1998; 275 (1): G85-G94.
113. Ruemmele FM, Schwartz S, Seidman EG, Dionne S, Levy E, Lentze MJ. Butyrate induced Caco-2 cell apoptosis is mediated via mitochondrial pathway. Gut 2003; 52(1): 94-100.
114. Hughes R, Rowland IR. Stimulation of apoptosis by two prebiotics chicory fructans in the rat colon. Carcinogenesis 2001; 22(1): 43-7.
115. Perrin P, Pierre F, Patty Y, Champ M, Berreur M, Pradal G, et al. Only fibres promoting a stable butyrate producing colonic ecosystem decrease tile rate of aberrant crypt foci in rats. Gut 2001; 48: 53-61.
116. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 2000; 66 (4): 1654-61.
117. Suau A, Bonnet R, Sutren M, Godon J-J, Gibson GR, Collins MD, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999; 65: 4799-807.
118. Chadwick VS, Anderson RP. Tile role of intestinal bacteria in etiology and maintenance of inflammatory bowel disease. In Gibson GR, Macfarlane GT Eds, Human colonic bacteria: role in nutrition, physiology and pathology. Boca Raton CRC Press 1995; 227-56.
119. Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflammatory Bowel Disease 2003; 10: S16-S24.
120. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infection and Immunity 1981; 32: 225-31.
121. Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulfate-reducing bacteria in gut contents from healthy subject and patients with ulcerative colitis. FEMS Microbiol Ecolog 1991; 86: 103-12.
122. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North A 1995; 24: 475-507.
123. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomised, placebo controlled trial. Gut 1997; 40: 485-91.
124. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002; 17(8): 818-24.
125. Araki Y, Andoh A, Fujiyama Y, Kanauchi O, Bamba T. Effects of germinated barley foodstuff on microllora and short chain fatty acid production in dextran sulfate sodium-induced colitis in rats. Biosci Biochem 2000; 64: 1794-1800.
126. Buddington KK, Donaboo JB, Buddington RK. Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers. J Nutr 2002; 132(3): 472-7.
127. Brück WM, Graverholt G, Gibson GR. Use of batch culture and a two-stage continuous culture system to study the effect of supplemental α-lactalbumin and glycomacropeptide on mixed populations of human gut bacteria. FEMS Microbiol Ecol 2002; 41: 231-7.
128. Idota T, Matsuoka Y, Sugawara M, Murakami Y, Ii N, Doki R, et al. Changes in the content of N-acetylneuraminic acid in human milk during lactation. J Jpn Soc Nutr Food Sci 1994; 47: 687-94.
129. Kawakami H. Biological significance of sialic acid-containing substances in milk and their application. Recent Res. Devel In Agricult Biolog Chem 1997; 1: 193-208.
130. Kawasaki Y, Isoda H, Tanimoto M, Dosako S, Idota T, Ahiko K. Inhibition by lactoferrin and κ-casein glycomacropeptide of binding of Cholera toxin to its receptor. Biosci Biotech Biochem 1992; 56: 195-8.
131. Azuma N, Yamauchi K, Mitsuoka T. Bifidus growth-promoting activity of a glycomacropeptide derived from human κ-casein. Agricult Biolog Chem 1985; 48: 2159-62.
132. Idota T, Kawakami H, Nakajima I. Growth-promoting effects of N-acetyineuraminic acid-containing substances on bifidobacteria. Biosci Biotech Biochem 1994; 58(9): 1720-2.
133. Dai D, Walker WA. Protective nutrients and bacterial colonisation in the immature human gut. Advances in Pediatrics 1999; 46: 353-82.
134. Gewolb IH, Schwalbe RS, Taciak VL, Harrison TS, Panigrahi P. Stool microflora in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1999; 80: F167-F73.
135. Butel MJ, Roland N, Hibert A, Popot F, Favre A, Tessedre AC, et al. Clostridial pathogenicity in experimental necrotising enterocolitis in gnotobiotic quails and protective role of bifidobacteria. J Med Microbiol 1998; 47(5): 391-9.
136. Szylit O, Butel M-J, Rimbault A. An experimental model of necrotising enterocolitis. The Lancet 1997; 350: 33-4.
137. Butel MJ, Waligora-Dupriet AJ, Szylit O. Oligofructose and experimental model of neonatal necrotising enterocolitis. Br J Nutr 2002; 87 (Suppl 2): S213-9.
138. Boelim G, Lidestri M, Casetta P, Jelinek J, Negretti F, Stahl B, et al. Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants. Arch Dis Child Fetal Neonatal Ed 2002; 86(3): F178-81.
139. Yamashita K, Kawai K, Itakura M. Effects of fructo-oligosaccharides on blood glucose and serum lipids in diabetic subjects, Nutr Res 1984; 4: 961-6.
140. Luo J, Rizkalla SW, Alamowitch C, Boussairi A, Blayo A, Barry J-L, et al. Chronic consumption of short-chain fructooligosaccharides by healthy subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. Am J Clin Nut 1996; 63: 939-45.
141. Luo J, Van Yperselle M, Rizkalla SW, Rossi F, Bornet FRJ, Slama G. Chronic consumption of short-chain fructoolgosaccharides does not affect basal hepatic glucsoe production ort insulin resistance in type 2 diabetics. J Nut 2000; 130: 1572-7.
142. Alles MS, deRoos NM, Bakx JC, van de Lisdonl E, Zock PL, Hautvast GA. Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. Am J Clin Nut 1999; 69: 64-69.
143. Delzenna NM, Williams CM. Prebiotics and lipid metabolism. Curr Opin Lipidol 2002; 13: 61-67.
144. Williams CM, Jackson KG. Inulin and oligofructose: effects on lipid metabolism from human studies. Br J Nutr 2002; 87: S261-4.
145. Davidson MH, Maki KC, Synecki C. Evaluation of the influence of dietary inulin on serum lipids in adults with hypercholesterolemia. Nutrition 1998; 18: 503-17.
146. Pereira DIA, Gibson GR. Effects of consumption of probiotics and prebiotics on serum lipids levels in humans. Crit Rev Biochem Mol Biol 2002; 37: 259-81.
147. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nut 2000; 71: 1682S-7S
148. Scholz-Ahrens K, Schrezenmeir J. Inulin, oligofructose and mineral metabolism - experimental data and mechanism. British Journal of Nutrition 2000; 87: S186-S219.
149. Trinidad TP, Wolever TM, Thompson LU. Effect of acetate and propionate on calcium absorption from the rectum and distal colon of humans. Am J Nut 1996; 63: 574-8.
150. Tahiri M, Tressol JC, Arnaud J, Bornet FRJ, Bouteloup-Demange C, Feillet-Coudray C, et al. Effect of short chain fructooligosaccharides on intestinal calcium absorption and calcium status in postmenauposal women: a stable-isotope study. Am J Clin Nut 2003; 77: 449-57.
151. Griffin IJ, Davila PM, Abrams SA. Non-digestible oligosaccharides and calcium absorption in girls with adequate calcium intakes. B J Nut 2002; 87: S187-91.
152. Coudray C, Demigne C, Rayssiguier Y. Effects of dietary fibers on magnesium absorption in animals and humans. J Nut 2003; 133: 1-4.
153. Scholz-Ahrens KE, Schaafsma G, van den Heuvel EG, Schrezenmeir J. Effects of prebiotics on mineral metabolism. Am J Clin Nut 2001; 73: 459S-64S.
154. van Loo J, Coussement P, de Leenheer L, Hoebregs H, Smits G. On the presence of insulin and oligofructose as natural ingredients in the western diet. Crit Rev Food Sci Nutr 1995; 35: 525-552.
155. Roberfroid MB, Functional effects of food components and the gastro-intestinal system: chicory fructo-oligosaccharides. Nutr Rev 1996; 54(11 Pt 2): S38-42
156. Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, et al. Short-chain fructo-oligosaccharide administration dose-dependantly increases fecal bifidobacteria in healthy humans. J Nut 1999; 129: 113-6.
157. Federal Food, Drug, and Cosmetic Act (FFDCA). United States of America, Public Law 1938; 75-717.
158. Dietary Supplement Health and Education Act of 1994 (DSHEA). United States of America Public Law 1994; 101-535.
159. Ross S. Functional foods: the Food and Drug Administration perspective. Am J Clin Nut 2000; 71: 1735S-8S.
160. Freitas M, Tavan E, Cayuela C, Diop L, Sapin C, Trugnan G. Host-pathogen cross-talk. Indigenous bacteria and probiotics also play the game. Biol Cell 2003; 95: 503-506.
161. van Ommen B, Stierum R. Nutrigenomics: exploiting systems biology in the nutrition and health area. Curr Opin Biotechnol 2002; 13: 517-521.
162. Gibson GR, Fuller R. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J Nutr 2000; 130: 391S-5S.
163. Kruse HP, Kleesen B, Blaut M. Effect of inulin on faecal bifidobacteria in human subjects. Br J Nutr 1999; 82(5): 375-82.
164. Kleessen B, Sykura B, Zunft HJ, Blaut M. Effects of inulin and lactose on faecal microflora, microbial activity and bowel habit in elderly constipated persons. Am J Clin Nutr 1997; 65(5): 1397-402.
165. Den Hond E, Geypens B, Ghoos. Effect of high performance chicory inulin on constipation. Nutr Res 2000; 20(5): 731-736.
166. Buddington RK, Williams CH, Chen SC, Witherly SA. Dietary supplement of neosugar alters the faecal flora and decreases activities of some reductive enzymes in human subjects. Am J Clin Nutr 1996; 63(5): 709-16
167. Williams CH, Witherly SA, Buddington RK. Influence of dietary neosugar on selected bacterial groups of the human faecal microbiota. Microb Ecol Health Dis 1994; 7: 91-7.
168. Howard MD, Gordon DT, Garleb KA, Kerley MS. Dietary fructooligosaccharide, xylooligosaccharide and gum arabic have variable effects on cecal and colonic microbiota and epithelial cell proliferation in mice and rats. J Nutr 1995; 125: 2604-9.
169. Nagendra R, Viswanatha S, Arun Kumar S. Effect of feeding milk formula containing lactulose to infants on faecal bifidobacterial flora. Nut Res 1995; 15: 15-24.
170. Tuohy KM, Finlay RK, Wynne AG, Gibson GR. A humam volunteer study on the prebiotic effects of HP-Inulin - faecal bacteria enumerated using fluorescent in situ hybridisation (FISH). Anaerobe 2001; 7: 113-118.
171. Avci FY, Karst NA, Linhardt RJ. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties. Curr Pharm Design 2003; 9(28): 2323-35.
172. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Design 2003; 9(4): 333-46.
173. Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Design 2003; 9(16): 1309-23.